Gary J. Nabel - 25 Jun 2025 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Director
Issuer ticker: CADL
Reported as of: 25 Jun 2025
Net transaction value: +$24,999
SEC form: 4
Accepted by SEC: 26 Jun 2025, 08:30:06 UTC
Prior SEC filing: 18 Jun 2025
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-In-Fact for Gary J. Nabel

Key filing fact

Gary J. Nabel filed Form 4 for Candel Therapeutics, Inc. (CADL) on 26 Jun 2025.

Key facts

This page summarizes Gary J. Nabel's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Jun 2025, 08:30.

Change

Previous filing in this sequence was filed on 18 Jun 2025.
Current net transaction value: +$24,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867450 Primary reporting owner

Nabel Gary J.

Relationship: Director
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-In-Fact for Gary J. Nabel
Signature date: 26 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CADL transaction

Common Stock

Award

Transaction value: $24,999
Shares: +5,353
Change %
Price: $4.67
Shares after: 5,353
Date: 25 Jun 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025.